Lance A. Liotta

Clinical proteomics: Applications for prostate cancer biomarker discovery and detection.

Clinical potential of proteomics in the diagnosis of ovarian cancer.

Stromal therapy: the next step in ovarian cancer treatment.

Clinical proteomics: translating benchside promise into bedside reality.

Serum proteomic patterns for detection of prostate cancer.

Genomics and proteomics: application of novel technology to early detection and prevention of cancer.

Frozen protein arrays: a new method for arraying and detecting recombinant and native tissue proteins.

Proteomic evaluation of archival cytologic material using SELDI affinity mass spectrometry: potential for diagnostic applications.

Cancer's deadly signature.

The granulin-epithelin precursor/PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer.

Proteomic technologies to study diseases of the lymphatic vascular system.

Proteomic analysis at the bedside: early detection of cancer.

General keynote: proteomic patterns in sera serve as biomarkers of ovarian cancer.

Clinical proteomics for cancer biomarker discovery and therapeutic targeting.

Mass spectrometry-based diagnostics: the upcoming revolution in disease detection.

Proteomic applications for the early detection of cancer.

Protein microarrays: meeting analytical challenges for clinical applications.

Cancer: Out of air is not out of action.

Clinical applications of proteomics.

Fibronectin-based masking molecule blocks platelet adhesion.

Counterpoint: The vision for a new diagnostic paradigm.

Clinical applications of proteomics: proteomic pattern diagnostics.

Dilution of protein gel stain results in retention of staining capacity.

Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancer.

Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling.

Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate.

Drosophila screening model for metastasis: Semaphorin 5c is required for l(2)gl cancer phenotype.

Clinical proteomics: written in blood.

Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays.

Protein microarrays: molecular profiling technologies for clinical specimens.

Signal pathway profiling of prostate cancer using reverse phase protein arrays.

Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays.

Molecular diagnostics.

Clinical proteomics: application at the bedside.

Drosophila invasive tumors: a model for understanding metastasis.

Use of proteomic analysis to monitor responses to biological therapies.

Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.

Serum proteomics in cancer diagnosis and management.

Biomarker amplification by serum carrier protein binding.

Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray.

Blasting into the microworld of tissue proteomics: a new window on cancer.

Use of proteomic patterns to screen for gastrointestinal malignancies.

Trapping radioactive carbon dioxide during cellular metabolic assays under standard culture conditions: description of a unique gas-capturing device.

Proteomic analysis of lymph.

Ovarian cancer detection by logical analysis of proteomic data.

Profiling the activity of G proteins in patient-derived tissues by rapid affinity-capture of signal transduction proteins (GRASP).

STUDENTJAMA. Molecular technologies for personalized cancer management.

Proteomic approaches in cancer risk and response assessment.

SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer.

Clinical proteomics: revolutionizing disease detection and patient tailoring therapy.

An investigation into the human serum "interactome".

Toxicoproteomics: serum proteomic pattern diagnostics for early detection of drug induced cardiac toxicities and cardioprotection.

Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays.

Clinical proteomics and biomarker discovery.

Novel approaches to visualization and data mining reveals diagnostic information in the low amplitude region of serum mass spectra from ovarian cancer patients.

Protein microarray detection strategies: focus on direct detection technologies.

Lessons from Kitty Hawk: from feasibility to routine clinical use for the field of proteomic pattern diagnostics.

Anoikis: cancer and the homeless cell.

Tumor invasion and metastasis: getting more basic to come closer to the patient. An interview with Lance A. Liotta.

Mitochondrial proteome: cancer-altered metabolism associated with cytochrome c oxidase subunit level variation.

Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml.

A functional polymorphism in RGS6 modulates the risk of bladder cancer.

Opportunities for nanotechnology-based innovation in tissue proteomics.

Expression microdissection: operator-independent retrieval of cells for molecular profiling.

Biomarkers of ovarian tumours.

Proteomic analysis of human breast cancer tissue with laser-capture microdissection and reverse-phase protein microarrays.

Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy.

Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma.

Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma.

Importance of communication between producers and consumers of publicly available experimental data.

L-histidine inhibits production of lysophosphatidic acid by the tumor-associated cytokine, autotaxin.

A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis.

Pathology of the future: molecular profiling for targeted therapy.

Supra-additive growth inhibition by a celecoxib analogue and carboxyamido-triazole is primarily mediated through apoptosis.

Physiological mechanisms of tumor-cell invasion and migration.

Pegylated, steptavidin-conjugated quantum dots are effective detection elements for reverse-phase protein microarrays.

Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy.

CSF proteome: a protein repository for potential biomarker identification.

Reverse-phase protein microarrays for tissue-based analysis.

Manual exfoliation of fresh tissue obviates the need for frozen sections for molecular profiling.

A transforming growth factor-beta receptor-interacting protein frequently mutated in human ovarian cancer.

Analysis of albumin-associated peptides and proteins from ovarian cancer patients.

Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma.

Cancer proteomics: many technologies, one goal.

Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy.

Linking laboratory and clinical research: the development of molecularly targeted therapeutics inside the national cancer institute center for cancer research.

The promise of proteomics.

Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold.

Nanoparticles: potential biomarker harvesters.

A control theoretic paradigm for cell signaling networks: a simple complexity for a sensitive robustness.

The amplified peptidome: the new treasure chest of candidate biomarkers.

Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling.

Identification and characterization of endogenous Langerin ligands in murine extracellular matrix.

Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment.

Selective binding and enrichment for low-molecular weight biomarker molecules in human plasma after exposure to nanoporous silica particles.

Nanoporous surfaces as harvesting agents for mass spectrometric analysis of peptides in human plasma.

Technology insight: pharmacoproteomics for cancer--promises of patient-tailored medicine using protein microarrays.

Laser capture microdissection.

Secreted neutral metalloproteases of Bacillus anthracis as candidate pathogenic factors.

Breast cancer growth prevention by statins.

Physicochemically modified silicon as a substrate for protein microarrays.

The blood peptidome: a higher dimension of information content for cancer biomarker discovery.

Glia maturation factor gamma (GMFG): a cytokine-responsive protein during hematopoietic lineage development and its functional genomics analysis.

Lysophosphatidic acid down-regulates stress fibers and up-regulates pro-matrix metalloproteinase-2 activation in ovarian cancer cells.

Tumor vascular proteins as biomarkers in ovarian cancer.

Laser-capture microdissection.

Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival.

A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples.

The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology.

Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer.

A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis.

Nanotechnology in clinical proteomics.

Development of reverse phase protein microarrays for clinical applications and patient-tailored therapy.

Multidimensional metamorphosis of biomarker science.

Reverse-phase protein microarrays: application to biomarker discovery and translational medicine.

Laser capture microdissection technology.

Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance.

Proteins, drug targets and the mechanisms they control: the simple truth about complex networks.

Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation.

Putting the "bio" back into biomarkers: orienting proteomic discovery toward biology and away from the measurement platform.

Reverse phase protein microarrays for monitoring biological responses.

Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy.

Automated laser capture microdissection for tissue proteomics.

Reverse phase protein microarrays for theranostics and patient-tailored therapy.

Molecular network analysis using reverse phase protein microarrays for patient tailored therapy.

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements.

A portrait of tissue phosphoprotein stability in the clinical tissue procurement process.

Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type.

Application of physicochemically modified silicon substrates as reverse-phase protein microarrays.

Core-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkers.

Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures.

Reverse-phase protein microarrays for theranostics and patient tailored therapy.

Application of laser microdissection and reverse-phase protein microarrays to the molecular profiling of cancer signal pathway networks in the tissue microenvironment.

Quantitative cell signalling analysis reveals down-regulation of MAPK pathway activation in colorectal cancer.

Activated VEGF receptor shed into the vitreous in eyes with wet AMD: a new class of biomarkers in the vitreous with potential for predicting the treatment timing and monitoring response.

An initial characterization of the serum phosphoproteome.

Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer.

Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients.

The heme degradation pathway is a promising serum biomarker source for the early detection of Alzheimer's disease.

Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing.

Nanoparticle technology: amplifying the effective sensitivity of biomarker detection to create a urine test for hGH.

Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival.

Mass spectrometry analysis of the post-translational modifications of alpha-enolase from pancreatic ductal adenocarcinoma cells.

Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer.

Concentration and Preservation of Very Low Abundance Biomarkers in Urine, such as Human Growth Hormone (hGH), by Cibacron Blue F3G-A Loaded Hydrogel Particles.

Monitoring proteins and protein networks using reverse phase protein arrays.

Nanoparticle technology: Addressing the fundamental roadblocks to protein biomarker discovery.

Mass spectrometry-based protein biomarker discovery: solving the remaining challenges to reach the promise of clinical benefit.

Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy.

Tissue is alive: New technologies are needed to address the problems of protein biomarker pre-analytical variability.

Synthesis and characterization of hydrogel particles containing Cibacron Blue F3G-A.

Reverse phase protein microarrays advance to use in clinical trials.

The use of hydrogel microparticles to sequester and concentrate bacterial antigens in a urine test for Lyme disease.

Reverse-phase protein microarrays (RPPA) as a diagnostic and therapeutic guide in multidrug resistant leukemia.

A method for the selective isolation and enrichment of carrier protein-bound low-molecular weight proteins and peptides in the blood.

Mass spectrometry-based characterization of the vitreous phosphoproteome.

What is the malignant nature of human ductal carcinoma in situ?

A novel biomarker harvesting nanotechnology identifies Bak as a candidate melanoma biomarker in serum.

Discovery of mouse spleen signaling responses to anthrax using label-free quantitative phosphoproteomics via mass spectrometry.

Protein microarray analysis of mammary epithelial cells from obese and nonobese women at high risk for breast cancer: feasibility data.

Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples.

Proteomic analysis of pancreatic ductal adenocarcinoma cells reveals metabolic alterations.

Reverse phase protein microarrays: fluorometric and colorimetric detection.

Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation.

Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways.

One-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimens.

Reverse phase protein microarrays for clinical applications.

Phosphoprotein stability in clinical tissue and its relevance for reverse phase protein microarray technology.

Cancer biomarkers: closer to delivering on their promise.

Multifunctional core-shell nanoparticles: discovery of previously invisible biomarkers.

Proteomic analysis reveals Warburg effect and anomalous metabolism of glutamine in pancreatic cancer cells.

Laser capture microdissection: Arcturus(XT) infrared capture and UV cutting methods.

Inventions and patents: a practical tutorial.

Regulatory approval pathways for molecular diagnostic technology.

Small business development for molecular diagnostics.

Proteomic analysis of eccrine sweat: implications for the discovery of schizophrenia biomarker proteins.

The spectra count label-free quantitation in cancer proteomics.

MS analysis reveals O-methylation of L-lactate dehydrogenase from pancreatic ductal adenocarcinoma cells.

-Omics and cancer biomarkers: link to the biological truth or bear the consequences.

Improved data normalization methods for reverse phase protein microarray analysis of complex biological samples.

Laser capture microdissection for protein and NanoString RNA analysis.

Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping.

Role of km23-1 in RhoA/actin-based cell migration.

Cancer metabolism: what we can learn from proteomic analysis by mass spectrometry.

Attacking breast cancer at the preinvasion stage by targeting autophagy.

Elevated TNFR1 and serotonin in bone metastasis are correlated with poor survival following bone metastasis diagnosis for both carcinoma and sarcoma primary tumors.

Quantum dots for biomedical applications.

Mass spectrometric analysis reveals O-methylation of pyruvate kinase from pancreatic cancer cells.

Systems analysis of the NCI-60 cancer cell lines by alignment of protein pathway activation modules with "-OMIC" data fields and therapeutic response signatures.

Retinal pigment epithelium (RPE) exosomes contain signaling phosphoproteins affected by oxidative stress.

Dynamic protein pathway activation mapping of adipose-derived stem cell differentiation implicates novel regulators of adipocyte differentiation.

Mapping protein signal pathway interaction in sarcoma bone metastasis: linkage between rank, metalloproteinases turnover and growth factor signaling pathways.

Application of Analyte Harvesting Nanoparticle Technology to the Measurement of Urinary HGH in Healthy Individuals.

Cancer metabolism and mass spectrometry-based proteomics.

Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling.

Glioblastoma cell enrichment is critical for analysis of phosphorylated drug targets and proteomic-genomic correlations.

Integrated genomic and epigenomic analysis of breast cancer brain metastasis.

Multiplex Proteomic Analysis of Cells in Fine Needle Aspiration Specimens: How Soon Can We Expect to Individualize Therapy by Comparing Pre- and Posttreatment Biopsies?

Protein pathway analysis in Clinical Proteomics using protein microarrays.

Protein painting reveals solvent-excluded drug targets hidden within native protein-protein interfaces.